Cleared Dual Track

K221813 - Nova Allegro UACR Assay, Nova Allegro Analyzer (FDA 510(k) Clearance)

Nov 2024
Decision
881d
Days
Class 2
Risk

K221813 is an FDA 510(k) clearance for the Nova Allegro UACR Assay, Nova Allegro Analyzer. This device is classified as a Alkaline Picrate, Colorimetry, Creatinine (Class II - Special Controls, product code CGX).

Submitted by Nova Biomedical Corporation (Walham, US). The FDA issued a Cleared decision on November 19, 2024, 881 days after receiving the submission on June 22, 2022.

This device falls under the Chemistry FDA review panel. Regulated under 21 CFR 862.1225.

Submission Details

510(k) Number K221813 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 22, 2022
Decision Date November 19, 2024
Days to Decision 881 days
Submission Type Dual Track
Review Panel Chemistry (CH)
Summary Summary PDF

Device Classification

Product Code CGX — Alkaline Picrate, Colorimetry, Creatinine
Device Class Class II - Special Controls
CFR Regulation 21 CFR 862.1225